Meridian Bioscience Inc. (VIVO): Price and Financial Metrics
VIVO Price/Volume Stats
| Current price | $33.97 | 52-week high | $34.38 |
| Prev. close | $33.97 | 52-week low | $20.35 |
| Day low | $33.93 | Volume | 6,422,800 |
| Day high | $34.02 | Avg. volume | 973,737 |
| 50-day MA | $32.89 | Dividend yield | N/A |
| 200-day MA | $31.01 | Market Cap | 1.49B |
VIVO Stock Price Chart Interactive Chart >
Meridian Bioscience Inc. (VIVO) Company Bio
Meridian Biosciences is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. The company was founded in 1976 and is based in Cincinnati, Ohio.
Latest VIVO News From Around the Web
Below are the latest news stories about MERIDIAN BIOSCIENCE INC that investors may wish to consider to help them evaluate VIVO as an investment opportunity.
Meridian Biosciences Stock: Why I Moved On But May Go Back In (NASDAQ:VIVO)Meridian Biosciences released an update saying it set the closing date for its merger on Jan. 31. Read more on this deal and implications for investors. |
Meridian Bioscience stock gains after announcing Jan. 31 closing date for saleMeridian Bioscience (VIVO) rose 8% after it said its planned sale to SD Biosensor, SJL Partners is expected to close on Jan |
Meridian Bioscience sets closing date for $1.53 billion dealOn Monday, officials with Meridian Bioscience Inc., a provider of diagnostic testing and life science raw materials, announced their pending $1.53 billion merger with two South Korean-based firms will close Jan. 31. |
Meridian Bioscience Announces Anticipated Closing Date of the Pending MergerMeridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has entered into a side letter with the buyer, setting the closing date of Meridian's pending merger for January 31, 2023. |
Meridian Bioscience Fiscal Q4 Revenues Fall 14 Percent, Full-Year Revenues Grow 5 PercentThe firm''s diagnostics segment revenues climbed 14 percent year over year in fiscal Q4, while life sciences revenues were down 37 percent. |
VIVO Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 6.19% |
| 3-year | 97.96% |
| 5-year | 134.37% |
| YTD | 2.29% |
| 2022 | 62.79% |
| 2021 | 9.15% |
| 2020 | 91.30% |
| 2019 | -43.29% |
| 2018 | 28.02% |
Continue Researching VIVO
Want to see what other sources are saying about Meridian Bioscience Inc's financials and stock price? Try the links below:Meridian Bioscience Inc (VIVO) Stock Price | Nasdaq
Meridian Bioscience Inc (VIVO) Stock Quote, History and News - Yahoo Finance
Meridian Bioscience Inc (VIVO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...